Hello and welcome to the details of Pfizer-BioNTech to seek authorisation for third Covid-19 shot and now with the details
WASHINGTON, July 8 ― Pfizer and BioNTech announced yesterday they would seek regulatory authorisation for a third dose of their Covid-19 vaccine.
It comes after initial data from an ongoing trial showed a third shot pushed antibody levels five to 10 times higher against the original coronavirus strain and the Beta variant, first found in South Africa, compared to the first two doses alone, according to a statement.
“The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA (Food and Drug Administration), EMA (European Medicines Agency) and other regulatory authorities in the coming weeks,” the statement said.
In addition, the companies expect that a third dose will perform similarly well against the highly transmissible Delta strain, which is quickly becoming globally dominant.
Out of caution, the companies are also developing a Delta-specific vaccine, the first batch of which has been manufactured at BioNTech's facility in Mainz, Germany.
The companies anticipate the clinical studies will begin in August, subject to regulatory approvals.
The companies added that, based on drop-offs in efficacy seen in Israel after six months, they believe that a third dose may be needed within six to 12 months after full vaccination
“While protection against severe disease remained high across the full 6 months, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected,” the statement said. ― AFP
These were the details of the news Pfizer-BioNTech to seek authorisation for third Covid-19 shot for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.